In a study by Sung et al., longitudinal cfDNA analysis lead to the detection of EGFR T790M mutation emergence in 28.6% of NSCLC patients receiving EGFR TKI treatment [36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.